newsfilter
← Earnings
Earnings Releases·

Neumora Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash and cash equivalents were $85.7 million as of September 30, 2026, down from $182.5 million as of December 31, 2025.
    • Research and development expenses for the quarter were $22.6 million, a decrease from $40.5 million in the same period in 2025, driven by reduced clinical trial and personnel costs.
    • General and administrative expenses were $10.8 million for the quarter, down from $12.2 million in the same period in 2025, primarily due to lower personnel-related costs.
    • Net loss for the third quarter of 2026 was $34.4 million, compared to a net loss of $56.8 million in the same period in 2025.
    • Total operating expenses for the quarter were $33.4 million, compared to $57.7 million in the prior year period.
    • Net loss per share (basic and diluted) was $0.18 for the quarter, compared to $0.35 in the same period in 2025.
    • Interest expense for the quarter was $1.8 million, an increase from $0.7 million in the same period in 2025.
    • Interest income for the quarter was $0.8 million, down from $1.7 million in the same period in 2025.
    • Total liabilities were $76.5 million as of September 30, 2026, compared to $87.2 million as of December 31, 2025.
    • Total stockholders' equity was $18.6 million as of September 30, 2026, down from $103.9 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • The company is not providing updated financial runway guidance.
    • Neumora stated it will require substantial additional funding to continue operations and complete development and commercialization of product candidates.
    • There is no assurance that additional funding will be available or on favorable terms.
    • Management is actively evaluating options to fund lead programs through their next value inflection points.
  • Business Segments and Product Lines:

    • NMRA-215 (NLRP3 Inhibitor): An Investigational New Drug (IND) application was submitted to the FDA for the treatment of obesity and cardiometabolic disease. Preclinical data presented at ObesityWeek 2026 showed weight loss of up to 19% as a monotherapy and up to 26% in combination with semaglutide in diet-induced obesity mouse studies.
    • NMRA-511 (V1aR Antagonist): A multiple ascending dose (MAD) expansion cohort demonstrated a favorable safety profile with no serious adverse events for a 30 mg BID dose in healthy elderly participants. The 30 mg BID dose showed dose-proportional increases in exposure compared to the 20 mg BID dose from the Phase 1b study. The program is Phase 2 enabled, and data from the Phase 1b study was presented at the Neuroscience Education Institute Fall Congress.
    • NMRA-898 (M4 Positive Allosteric Modulator): The Phase 1 MAD study in healthy volunteers and patients with stable schizophrenia is ongoing.
  • Risks and Challenges:

    • The company faces risks related to the inherent uncertainty of clinical drug development, regulatory approval timelines, and the lengthy process for obtaining approvals.
    • Risks include delays in clinical trial initiation and enrollment, reliance on third-party contract research organizations (CROs), and potential serious or undesirable side effects of therapeutic candidates.
    • There are risks regarding the ability to protect intellectual property rights and the sufficiency of capital resources to fund operations.
    • There is no assurance that additional funding will be available to the company.
  • Management Commentary and Tone:

    • CEO Joshua Pinto, Ph.D., described the period as one of "strong execution" across the pipeline.
    • Management highlighted the submission of the NMRA-215 IND and NMRA-511 data as key milestones.
    • Pinto emphasized a disciplined approach to capital allocation, focusing on programs with the greatest potential to create value for patients and shareholders.
    • The tone indicates confidence in the efficacy profiles of NMRA-215 and NMRA-511 while acknowledging the need for external funding.
  • Other Key Points:

    • The company is a clinical-stage biopharmaceutical company targeting novel mechanisms of action for underserved brain diseases.
    • No revenue was generated in the quarter as the company is in the clinical stage.
    • The company filed its Quarterly Report on Form 10-Q with the SEC on the same date as the press release.
    • Weighted-average shares outstanding (basic and diluted) increased to 187.9 million for the quarter ended September 30, 2026, from 161.8 million in the same period in 2025.
Company
NEUMORA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology